More than 300 participants of the country’s “Mix and Match” (MnM) study have already received their first dose of Sinovac vaccine, the Department of Science and Technology (DOST) said Friday, Jan. 7.
The 18 month-long study seeks to evaluate the safety and immunogenicity of mixing different coronavirus disease (COVID-19) vaccines and vaccine platforms in Filipino adults. The project team is led by Dr. Michelle De Vera of the Philippine Society for Allergy, Asthma, and Immunology (PISAAI).
Locally available vaccines under the National Immunization Program have been used in the trial. These include Sinovac, Sputnik V, AstraZeneca, Pfizer and Moderna.
DOST Undersecretary for Research and Development Dr. Rowena Cristina L. Guevara said 332 participants got their first dose of Sinovac vaccines, while 86 participants were vaccinated with second dose of either Sinovac or Pfizer, Moderna, AstraZeneca, Sputnik V vaccines.
“As of January 5, 2022, the three sites in Marikina, Manila and Muntinlupa sites have already conducted their recruitment activities with a total of 332 vaccinated with first dose of Sinovac and 86 participants who have received their second dose of either a homologous (Sinovac) or heterologous (Pfizer, Moderna, AstraZeneca, Sputnik V) vaccines,” she said in an interview with the Manila Bulletin.
Guevara disclosed that in addition to Marikina, Manila and Muntinlupa trial sites, there were two other sites being coordinated with their respective local government units (LGUs) for study approval or endorsement prior to the conduct of the trial.
Around 3,000 adult volunteers aged 18 and above were targeted to participate in the study.
The MnM study has been given a total budget of P204.19 million under the DOST-Grants-in-Aid (GIA) program. It secured FDA's approval on Nov. 16.
The study is aimed at determining the safety and immunogenicity of completing the vaccination series with available COVID-19 vaccines in the Philippines in those given Sinovac as the first dose.
The trial likewise seeks to analyze whether those who already completed the dosing regimen for Sinovac will have a better immune response after the immunization of a booster dose from a different vaccine platform or brand.